The minimum and maximum dose of BTX-A may vary depending on the muscle that is considered. It has been shown that BTX-A produces improvements in lower and upper limb function, thereby improving movement such as walking (see Figure 1) or fine motor skills. Intramuscular injection of BTX-A is a standard treatment for spasticity. Spasticity is a motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks resulting from the hyper-excitability of the stretch reflexes as one component of upper motor neuron syndrome. For this reason, physicians often advise people with such impairments to be treated in rehabilitation as a supplement to their background pharmacologic treatment.
The gating mechanism is efficient in modeling treatment interaction and improving trajectory prediction.įatigue, weakness, sensory loss, ataxia, and spasticity are among the usual causes of motor impairments due to neurological diseases such as multiple sclerosis (MS), TBI, spinal cord injury (SCI), and CP, among others. The MTL models outperformed the serial models, particularly when introducing treatment metadata. To the best of our knowledge, this is the first time that MTL has been used for post-treatment gait trajectory prediction.
Overall, the best RMSE ranged from 5.24° to 6.24° for the MTL models. Multi-task learning (MTL) achieved the lowest root-mean-squared error (RMSE) (5.60°) for traumatic brain injury (TBI) patients on knee trajectories and the lowest RMSE (3.77°) for cerebral palsy (CP) patients on ankle trajectories, with only a difference of 5.60° between actual and predicted. The proposed models were compared with and without metadata describing treatments and with serial models. For the prediction of knee and ankle kinematics after botulinum toxin type A (BTX-A) treatment, we propose: (1) a regression strategy based on a multi-task architecture composed of LSTM models (2) to introduce medical treatment data (MTD) for context modeling and (3) a gating mechanism to model treatment interaction more efficiently. According to the patient’s profile, offering the optimal treatment combined with the highest possible benefit-risk ratio is important. Intramuscular injection of botulinum toxin type A is a common treatment for spasticity. A typical consequence of such diseases is gait disorders, partially explained by command and muscle tone problems associated with spasticity. We propose a framework for optimizing personalized treatment outcomes for patients with neurological diseases.
0 kommentar(er)
